ScholarIQanswers from OpenAlex
Instituto Nacional de Cancerología
InstitutionResearch output, impact & collaborations
Instituto Nacional de Cancerología is a institution indexed in ScholarIQ from OpenAlex.
What is known about Instituto Nacional de Cancerología?
ScholarIQrecord summary
Instituto Nacional de Cancerología is a research organisation in Bogotá, CO. OpenAlex records 2,883 works and 147,300 citations for it. 1,597 researchers list it as their most recent affiliation.
How many works does Instituto Nacional de Cancerología have?
ScholarIQindexed works
Instituto Nacional de Cancerología has 2,883 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Instituto Nacional de Cancerología have?
ScholarIQcitation count
Instituto Nacional de Cancerología has 147,300 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Instituto Nacional de Cancerología?
ScholarIQresearcher count
Instituto Nacional de Cancerología has 1,597 researchers in the ScholarIQ index.
What is the average h-index at Instituto Nacional de Cancerología?
ScholarIQavg h-index
Instituto Nacional de Cancerología has an average h-index of 44.5 in OpenAlex.
What is the ROR of Instituto Nacional de Cancerología?
ScholarIQror
The ROR for Instituto Nacional de Cancerología is on the source record.
What is the OpenAlex record for Instituto Nacional de Cancerología?
ScholarIQopenalex
The OpenAlex for Instituto Nacional de Cancerología is on the source record.
Who are the most-cited researchers behind Instituto Nacional de Cancerología?
ScholarIQtop researchers by citations
What are the most-cited papers on Instituto Nacional de Cancerología?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Lucely Cetina, José Luis Aguilar-Ponce, Óscar Arrieta, Aurora González‐Fierro, Alma Chávez‐Blanco, Erik de la Cruz-Hernandez, Maria Fernanda Vieira Cunha Camargo, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, Carlos Pérez‐Plasencia, Lucía Taja‐Chayeb, Talía Wegman-Ostrosky, Alma Luísa Revilla Vázquez, Alfonso Dueñas‐González
How much of the research on Instituto Nacional de Cancerología is open access?
ScholarIQopen access share
75%OPEN ACCESS